SynthesisCancer imaging : the official publication of the International Cancer Imaging Society2015
Prognostic significance of (18)FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis.
Synthesis in Cancer imaging : the official publication of the International Cancer Imaging Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Advances and prospects in deuterium metabolic imaging (DMI): a systematic review of in vivo studies.European radiology experimental · 2024Pooled it
- The prognostic utility ofFrontiers in immunology · 2024Pooled it
- Pooled it
- Calpain Small Subunit 1 Protein in the Prognosis of Cancer Survivors and Its Clinicopathological Correlation.BioMed research international · 2019Pooled it
- Pooled it
- Prognostic value of 18F-FDG-PET/CT in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis.Oncotarget · 2017Pooled it
- Comprehensive literature review of oral and intravenous contrast-enhanced PET/CT: a step forward?Frontiers in medicine · 2024Review
- PET/CT in assessment of colorectal liver metastases: a comprehensive review with emphasis onClinical & experimental metastasis · 2023Review
- Article
- Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis.Cancer medicine · 2023Article
- FDG metabolic parameter-based models for predicting recurrence after upfront surgery in synchronous colorectal cancer liver metastasis.European radiology · 2023Article
- A deep learning model based on the attention mechanism for automatic segmentation of abdominal muscle and fat for body composition assessment.Quantitative imaging in medicine and surgery · 2023Article
- FDG-PET/CT in colorectal cancer: potential for vascular-metabolic imaging to provide markers of prognosis.European journal of nuclear medicine and molecular imaging · 2021Observational
- Comprehensive Imaging Characterization of Colorectal Liver Metastases.Frontiers in oncology · 2021Review
- Liver transplantation for non-resectable colorectal liver metastasis: where we are and where we are going.Langenbeck's archives of surgery · 2020Review
- Current state of the art imaging approaches for colorectal liver metastasis.Hepatobiliary surgery and nutrition · 2020Review
- [Importance of FDG-PET/computed tomography in colorectal cancer].Der Radiologe · 2019Review
- Colorectal liver metastases: An update on multidisciplinary approach.World journal of hepatology · 2019Review
- Prognostic Value of MTV, SUVmax and the T/N Ratio of PET/CT in Patients with Glioma: A Systematic Review and Meta-Analysis.Journal of Cancer · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of 18-fluorodeoxyglucose positron emission tomography CT ((18)FDG PET/CT), as a prognostic factor for survival in colorectal cancer patients with liver metastases, is still controversial. We sought to perform a meta-analysis of the literature to address this issue.
methodsA systematic literature search was performed to identify the studies that associated (18)FDG PET/CT to clinical survival outcomes of patients with liver metastases. Methodological qualities of the included studies were also assessed. The summarized hazard ratio (HR) was estimated by using fixed- or random-effect model according to heterogeneity between trails.
resultsBy analyzing a total of 867 patients from 15 studies, we found that PET/CT for metabolic response to the therapy was capable of predicting event-free survival (EFS) and overall survival (OS) with statistical significance, and the HR was 0.45 (95% confidence interval [CI], 0.26-0.78) and 0.36 (95% CI, 0.18-0.71), respectively. Furthermore, pre-treatment (18)FDG PET/CT with high standardized uptake value (SUV) was also significantly associated with poorer OS HR, 1.24; (95% CI, 1.06-1.45). However, we did not find a statistically significant effect of post-treatment SUV for predicting OS HR, 1.68; (95% CI, 0.63-4.52).
conclusionsThe present meta-analysis confirms that (18)FDG PET/CT is a useful tool to help predict survival outcomes in patients with liver metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.